Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 8/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL111600 | 0.98 | PRMT3 (0.62) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL16634909 | 0.88 | PRMT3 (0.61) | PRMT3IMPDH2NOTUM | |
| SCHEMBL20262924 | 0.87 | KDM4E (0.66) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL30176801 | 0.87 | KDM4E (0.66) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL19860095 | 0.86 | IMPDH2 (0.62) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL19860105 | 0.86 | PRMT3 (0.62) | PRMT3IMPDH2NOTUM | |
| SCHEMBL14157781 | 0.85 | CYP3A4 (0.65) | — | |
| SCHEMBL2162755 | 0.85 | NOTUM (0.62) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL12201759 | 0.85 | IMPDH2 (0.61) | PRMT3IMPDH2NOTUMROCK2ROCK1 | |
| SCHEMBL19860096 | 0.85 | NOTUM (0.65) | PRMT3IMPDH2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | disclosed |
| US-11197853-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210236477-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2021-08-05 | — | — | US | disclosed |
| US-11020385-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200129498-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2020-04-30 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9890123-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-1910297-B1 | ISOQUINOLINE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8455513-B2 | Kinase inhibitors; anticarcinogenic agents; obesity, glaucoma; N-(4-(3-(isoquinolin-6-ylamino)-3-oxopropyl)phenyl)-4-methoxybenzamide | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8034943-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | PRMT3 1452/4885IMPDH2 236/4885NOTUM 3447/4885 |
| US-11020385-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | PRMT3 4083/4885IMPDH2 440/4885NOTUM 2574/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
| US-20220088000-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PRMT3 4083/4885IMPDH2 440/4885NOTUM 2574/4885 |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
| US-20210236477-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PRMT3 4083/4885IMPDH2 440/4885NOTUM 2574/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
| US-20200129498-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PRMT3 4083/4885IMPDH2 440/4885NOTUM 2574/4885 |
| US-11197853-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | PRMT3 4083/4885IMPDH2 440/4885NOTUM 2574/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | PRMT3 1026/4885IMPDH2 2131/4885NOTUM 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.